Juanjo Garcés
@juanjogrcs
Happy are those who know how to laugh at themselves, because they will always end up having fun. Thomas More #postdoc in #mmsm at @sloan_kettering
Definitely, we need more #basicResearch in #mmsm. Promising study! febs.onlinelibrary.wiley.com/doi/10.1002/18…
It was fun to work with @RossFirestone in writing this editorial for @BloodPortfolio #Blood "More than myeloma: the trouble with “normal” plasma cells", on the recent article from @nickbolli @matteoclaudio84 sciencedirect.com/science/articl… @MSKCancerCenter @MSK_DeptOfMed #mmsm
Longitudinal ctDNA from S1826 #18ICML: - ctDNA drops significantly by C3D1 - detectable ctDNA at C3D1 & EOT both very prognostic - minor drop in ctDNA (<3 log) at interim w/ very poor prognosis Response adapted future trials! #lymsm
CONGRESS | #EHA2025 | PRESENTATION Shaji Kumar @myelomaMD @MayoClinic presents results from the phase II RedirecTT-1 trial of talquetamab + teclistamab in patients with RRMM with EMD. Tal + Tec led to an ORR of 78.9% and a ≥CR rate of 54.4%; efficacy exceeded standard therapies,…
CONGRESS | #EHA2025 | PRESENTATION Ian Márquez López, @idibaps, presents insights into the clonal architecture of CLL providing new perspectives on the origin and evolution of CLL. CLL clones seem to arise from distinct cells of origin and start to expand decades before…
Dr. Rajesh Popat updating JNN-5322 at #EHA2025. Robust responses: 100% ORR at RP2D with CR ≥ 70.4%, approaching that of MM CARTs. The usual GPRC5D-related AEs (ex. loss of taste) were not seen, possible due to tight preferential dual targeting to tumor. Safety as expected #mmsm
Congratulations to the best award receivers at #EHA2025, especially Noelia Collado-Gisbert (aka, @carmengonzalez 😂) and @LucaBertamini!
#EHA2025 CTC session in myeloma and amyloidosis #mmsm CTCs are fighting for a sit on the table of routine staging of these patients. Congrats Ioannis Kostopoulos, @juanjogrcs @LucaBertamini @DZihala @TomasJelinekMD @Dagostino_MD
#CTCs are on fire at #EHA2025. Now, @LucaBertamini presents the biggest consortium up to date!
Almost ready to present our work about #CTCs at #EHA2025, come to learn about how #liquidbiopsies can change the paradigm of #mmsm!
Very proud of seeing Dr San-Miguel receiving this prestigious award at #EHA2025 . Well deserved by his scientific contributions and, I'd dare to say, by his close and extremely valuable supervision!
Happy to share our new work out today on @BloodPortfolio #Blood where we report CD38 loss as recurrent mechanisms of resistance to anti-CD38 antibody in multiple myeloma. Great collaboration between @MSKCancerCenter @MSK_DeptOfMed @UCalgary @HDMyeloma @MayoClinic #mmsm #wgs
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…
🚨 #EHA2025 is nearly here! The list of top abstracts selected by the #MultipleMyeloma Hub Steering Committee for the EHA 2025 Congress is now available to view 👉 loom.ly/xKkySy4 #mmsm
Excited to share our work investigating the mutagenic impact of radiotherapy in hematological cancers out today in @BCD_AACR!! 🎉 Another study born from amazing collaborations across @MoffittNews @HDMyeloma @univmiami @MSKCancerCenter @MSK_DeptOfMed 💪 #lysm #wgs #RT #mmsm